Skip to content

Comprehensive Imaging Exam of Convalesced COVID-19 Patients

Comprehensive Imaging Exam of Convalesced COVID-19 Patients

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05920616
Enrollment
206
Registered
2023-06-27
Start date
2020-10-14
Completion date
2026-05-15
Last updated
2026-06-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19, COVID Long-Haul

Brief summary

COVID-19 is a systemic inflammatory disease involving many organs including the lungs, vascular system liver and myocardium that lead to severe pathologies. Patients with severe cardiopulmonary symptoms usually require weeks to months to fully recover. Studies of clinical and subclinical impairments of COVID-19 patients are important for medical practice and public health as well as providing pathogenic insight to the viral infection and secondary immune response. Chronic damage of vital organs and systems, and the potential long-term effects is of serious concern. In this study the investigators plan to quantify and characterize chronic consequences of COVID-19 in individuals who receive similar medical care related to disease severity and duration in a single health care system. Using state-of-the-art Computed Tomography (CT) and Magnetic Resonance Imaging (MRI) technology, we will study the pathology in major organ systems in comparison to matched controls. The results of this study may facilitate measures to prevent, detect, and manage complications from COVID-19 infections.

Detailed description

As the number of recovered COVID-19 patients increase around the globe, it is important to understand the longterm impact of the disease so that healthcare systems and providers can optimize follow-up care of these patients. Identifying long term effects may also help identify patients with an increased risk of major adverse events following discharge from the hospital. Currently, the long term effects of COVID-19 in discharged hospitalized patients remain unknown. Infection with COVID-19 may result in involvement of many organ systems, including the lung, heart, brain, liver, and kidneys. Patients with a previous history of cardiovascular disease have been found to be at higher risk for incident cardiovascular complications. Direct or indirect effects of COVID-19 infection may predispose patients to thrombotic events including acute myocardial injury or pulmonary defects. Cardio-pulmonary features of COVID-19 include: bilateral multilobar ground-glass opacifications, septal thickening, bronchiectasis, pleural thickening, and subpleural involvement. Gradual resolution of consolidative opacities and other imaging patterns associated with clinical improvement usually occur after the second week of the disease. Characterization and quantification of organ injury as well associated organ dysfunction may help facilitating appropriate prevention and management.

Interventions

OTHERMagnetic Resonance Imaging

Completion of Magnetic Resonance Imaging of the brain, heart, lungs, and liver with and without contrast.

OTHERUltra-High Resolution Computed Tomography (CT) Scan

Completion of a high resolution CT scan of the lungs and high resolution CT of the coronary arteries.

Sponsors

Johns Hopkins University
Lead SponsorOTHER
Canon Medical Systems, USA
CollaboratorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age: 18+ * Diagnosed with COVID-19 at any point starting March 2020. * Subgroup A: hospitalized due to COVID-19 infection * Subgroup B: non-hospitalized

Exclusion criteria

* Known allergy to either gadolinium or iodine based contrast agents * Glomerular Filtration Rate (GFR) \<45 mL/min (using the Cockcroft-Gault formula) * Pregnancy * Internal electrical devices, such as cochlear implant, spinal cord stimulator, pacemaker, or defibrillator * Atrial fibrillation, uncontrolled tachyarrhythmia or advanced atrioventricular block (2nd or 3rd degree) at time of imaging * Evidence of severe symptomatic heart failure (NYHA Class III or IV) at the time of imaging * Other acute illness * Ongoing mechanical ventilation related to hospitalization for COVID-19 related illness * Presence of any other history or condition that the investigator feels would be problematic * Weight exceeding 300 lbs (MRI table weight restrictions) * Severe claustrophobia

Design outcomes

Primary

MeasureTime frameDescription
Degree and extent of fibrosisAnalyzed within 6 months of study completion\- MRI to assess degree and extent of fibrosis in the liver, lungs, brain, myocardium, and vascular systems

Secondary

MeasureTime frameDescription
Assessment of PerfusionAnalyzed within 6 months of study completionUltra-High Resolution CT to assess the amount of perfusion to the lungs and heart.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJoao Lima, MD

Johns Hopkins School of Medicine

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 11, 2026